Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1876]
News [4315]
Articles [404]
Editorials [10]
Conferences [107]
elearning [41]
Phase III trial did not show superiority of eribulin compared with capecitabine...
Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA
Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer ( Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA )
12 Dec 2012
HDAC inhibitors sensitise triple-negative breast cancer cells to PARP...
Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA
HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment ( Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA )
6 Dec 2012
Diverse genetic alterations in triple-negative breast cancers after neoadjuvant...
Dr Justin Balko - Vanderbilt-Ingram Cancer Center, Nashville, USA
Diverse genetic alterations in triple-negative breast cancers after neoadjuvant chemotherapy ( Dr Justin Balko - Vanderbilt-Ingram Cancer Center, Nashville, USA )
6 Dec 2012
Young women with breast cancer more likely to respond to neoadjuvant...
Prof Sibylle Loibl - University of Frankfurt, Frankfurt, Germany
Young women with breast cancer more likely to respond to neoadjuvant chemotherapy ( Prof Sibylle Loibl - University of Frankfurt, Frankfurt, Germany )
6 Dec 2012
Chemo after complete surgical removal of local or regional breast cancer...
Dr Stefan Aebi - Luzerner Kantonsspital, Luzern, Switzerland
Chemo after complete surgical removal of local or regional breast cancer recurrence increases survival rates ( Dr Stefan Aebi - Luzerner Kantonsspital, Luzern, Switzerland )
6 Dec 2012
Fewer, bigger doses of radiotherapy benefit cancer patients
Prof John Yarnold - Institute of Cancer Research and Royal Marsden Hospital, UK
Fewer, bigger doses of radiotherapy benefit cancer patients ( Prof John Yarnold - Institute of Cancer Research and Royal Marsden Hospital, UK )
6 Dec 2012
New genetic sub-types of breast, ovarian and prostate cancer
Dr Paul Pharoah – University of Cambridge, UK
New genetic sub-types of breast, ovarian and prostate cancer ( Dr Paul Pharoah – University of Cambridge, UK )
14 Nov 2012
Benefits of participating in clinical trials and patient liaison groups
Shirley Harrison - VNCRI and NCRN Consumer Liaison Groups
Benefits of participating in clinical trials and patient liaison groups ( Shirley Harrison - VNCRI and NCRN Consumer Liaison Groups )
14 Nov 2012
Effects of aspirin on the progression of cancer
Prof Peter Rothwell – Oxford University, UK
Effects of aspirin on the progression of cancer ( Prof Peter Rothwell – Oxford University, UK )
1 Nov 2012
Progress of personalised oncology treatment
Prof Martine Piccart – President-Elect of ECCO
Progress of personalised oncology treatment ( Prof Martine Piccart – President-Elect of ECCO )
22 Oct 2012
Analysing the efficacy of treatment through Response Evaluation Criteria in...
Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012
Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype
Dr Fatima Cardoso – Champalimaud Cancer Center, Lisbon, Portugal
Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype ( Dr Fatima Cardoso – Champalimaud Cancer Center, Lisbon, Portugal )
9 Oct 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation